Comparative Trials

Animal-derived surfactants for the treatment and prevention of neonatal respiratory distress syndrome: summary of clinical trials

J Wells Logan and Fernando R Moya

Clinical trials suggest that the higher surfactant protein-B content in calfactant, and perhaps the higher phospholipid content in poractant (at higher initial dose), are the factors that most likely confer the observed advantage over other surfactant preparations.

View study: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2697515/

Efficacy of surfactant-TA, calfactant and poractant alfa for preterm infants with respiratory distress syndrome: a retrospective study

J Wells Logan and Ga Won Jeon 1, Minkyung Oh 2, Jong Beom Sin 3

Calfactant is equally as effective as surfactant-TA and poractant alfa. This was the first study comparing the efficacy of surfactant-TA, calfactant, and poractant alfa in a large number of preterm infants in Korea. Further randomized prospective studies on these surfactants are needed.

View study: https://pubmed.ncbi.nlm.nih.gov/25683992/

Comparative effectiveness of surfactant preparations in premature infants

J Andrea Trembath 1, Christoph P Hornik, Reese Clark, P Brian Smith, Julie Daniels, Matthew Laughon; Best Pharmaceuticals for Children Act—Pediatric Trials Network

Beractant, calfactant, and poractant alfa demonstrated similar effectiveness in prevention of air leak syndromes, death, and BPD or death in premature infants when adjusted for site. Previously described differences in mortality between surfactants likely do not represent true differences in effectiveness but may relate to site variation in outcomes.

View study: https://pubmed.ncbi.nlm.nih.gov/23769501/

Comparison of the Pharmacoeconomics of Calfactant and Poractant Alfa in Surfactant Replacement Therapy

Michael M. Zayek, MD,corresponding author Fabien G. Eyal, MD, and Robert C. Smith, BScPharm, MS

Our experience showed a strong pharmacoeconomic advantage for the use of calfactant compared to the use of poractant alfa because of similar average dosing and lower per patient drug costs.

View study: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5916443/

Comparison of Infasurf (calf lung surfactant extract) to Survanta (Beractant) in the treatment and prevention of respiratory distress syndrome

B T Bloom 1, J Kattwinkel, R T Hall, P M Delmore, E A Egan, J R Trout, M H Malloy, D R Brown, I R Holzman, C H Coghill, W A Carlo, A K Pramanik, M A McCaffree, P L Toubas, S Laudert, L L Gratny, K B Weatherstone, J H Seguin, L D Willett, G R Gutcher, D H Mueller, W H Topper

Infants treated with Infasurf have a modest benefit in the acute phase of RDS. Infasurf seems to produce a longer duration of effect than Survanta.

View study: https://pubmed.ncbi.nlm.nih.gov/9200357/